AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

Recruiting

Phase 3

AZD5335 vs. Standard CareAZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

Sponsor:

AstraZeneca

Code:

NCT07218809

Conditions

Epithelial Ovarian Cancer

Eligibility Criteria

Sex: Female

Age: 18+

Healthy Volunteers: Not accepted

Interventions

AZD5335

Mirvetuximab Soravtansine (MIRV)

Paclitaxel

Pegylated liposomal Doxorubicin (PLD)

Topotecan

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-07-23. This information was provided to ClinicalTrials.gov by AstraZeneca on 2026-07-21.